Guangdi Li

List of Publications by Year
in descending order

50 papers	4,546 citations	218381 26 h-index	205818 48 g-index
50 all docs	50 docs citations	50 times ranked	9847 citing authors

#	Article	IF	Citations
1	Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharmaceutica Sinica B, 2022, 12, 1567-1590.	5.7	31
2	DsbA-L interacts with VDAC1 in mitochondrion-mediated tubular cell apoptosis and contributes to the progression of acute kidney disease. EBioMedicine, 2022, 76, 103859.	2.7	13
3	The ILâ€21â€TET2â€AIM2â€câ€MAF pathway drives the T follicular helper cell response in lupusâ€like disease. Clinical and Translational Medicine, 2022, 12, e781.	1.7	20
4	Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. Immunity and Ageing, 2022, 19, 12.	1.8	23
5	Trends in the disease burden of HBV and HCV infection in China from 1990-2019. International Journal of Infectious Diseases, 2022, 122, 476-485.	1.5	31
6	Global Burden of Nutritional Deficiencies among Children under 5 Years of Age from 2010 to 2019. Nutrients, 2022, 14, 2685.	1.7	8
7	Antiviral Classification. , 2021, , 121-130.		10
8	Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecules, 2021, 26, 923.	1.7	21
9	Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. Biochemical Pharmacology, 2021, 185, 114485.	2.0	9
10	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicines, 2021, 9, 412.	1.4	22
11	Molecular mechanisms underlying hepatitis C virus infection-related diabetes. Metabolism: Clinical and Experimental, 2021, 121, 154802.	1.5	5
12	Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study. Aging, 2021, 13, 27-60.	1.4	49
13	A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951â€“2021). Medicinal Research Reviews, 2021, , .	5.0	6
14	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clinical Cancer Research, 2020, 26, 1712-1724.	3.2	76
15	Molecular epidemiology, phylogenetic analysis and genotype distribution of hepatitis B virus in Saudi Arabia: Predominance of genotype D1. Infection, Genetics and Evolution, 2020, 77, 104051.	1.0	10
16	Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 11-30.	1.5	90
17	Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2). Clinical and Translational Immunology, 2020, 9, e1182.	1.7	65
18	The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/Î²-catenin signaling pathway. Cellular and Molecular Immunology, 2020, 17, 1163-1179.	4.8	40

#	Article	IF	Citations
19	Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nature Human Behaviour, 2020, 4, 856-865.	6.2	281
20	DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nature Communications, 2020, 11, 4467.	5.8	51
21	Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 2759-2774.	2.0	19
22	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatology International, 2020, 14, 212-224.	1.9	26
23	C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. Oncogene, 2020, 39, 3354-3366.	2.6	10
24	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, 2020, 19, 149-150.	21.5	1,370
25	Clinical characteristics of older and younger patients infected with SARS-CoV-2. Aging, 2020, 12, 11296-11305.	1.4	25
26	Drivers of HIV-1 transmission: The Portuguese case. PLoS ONE, 2019, 14, e0218226.	1.1	12
27	Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 813-829.	1.5	57
28	The relationships among verbal ability, executive function, and theory of mind in young children with cochlear implants. International Journal of Audiology, 2018, 57, 881-888.	0.9	10
29	Obesity-Associated miR-199a/214 Cluster Inhibits Adipose Browning via PRDM16â€“PGC-1Î± Transcriptional Network. Diabetes, 2018, 67, 2585-2600.	0.3	39
30	Antifungal activity of spider venom-derived peptide lycosin-I against Candida tropicalis. Microbiological Research, 2018, 216, 120-128.	2.5	17
31	TRIM21 Promotes Innate Immune Response to RNA Viral Infection through Lys27-Linked Polyubiquitination of MAVS. Journal of Virology, 2018, 92, .	1.5	96
32	Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5. Journal of Virology, 2018, 92, .	1.5	60
33	APPLs: More than just adiponectin receptor binding proteins. Cellular Signalling, 2017, 32, 76-84.	1.7	39
34	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Research, 2017, 142, 83-122.	1.9	135
35	Rheb Inhibits Beiging of White Adipose Tissue via PDE4D5-Dependent Downregulation of the cAMP-PKA Signaling Pathway. Diabetes, 2017, 66, 1198-1213.	0.3	39
36	NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2. Journal of Virology, 2017, 91, .	1.5	62

#	Article	IF	Citations
37	HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiology and Molecular Biology Reviews, 2016, 80, 679-731.	2.9	61
38	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology, 2016, 26, 408-434.	3.9	34
39	Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evolution, 2016, 2, vew024.	2.2	17
40	Approved Antiviral Drugs over the Past 50 Years. Clinical Microbiology Reviews, 2016, 29, 695-747.	5.7	1,049
41	Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1â€“6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses, 2015, 7, 5018-5039.	1.5	59
42	An integrated map of HIV genome-wide variation from a population perspective. Retrovirology, 2015, 12, 18.	0.9	90
43	A new ensemble coevolution system for detecting HIV-1 protein coevolution. Biology Direct, 2015, 10, 1.	1.9	78
44	High-Throughput Analysis of Human Cytomegalovirus Genome Diversity Highlights the Widespread Occurrence of Gene-Disrupting Mutations and Pervasive Recombination. Journal of Virology, 2015, 89, 7673-7695.	1.5	148
45	Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. PLoS ONE, 2014, 9, e101738.	1.1	36
46	HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. Retrovirology, 2014, 11, 79.	0.9	11
47	A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. Antiviral Research, 2014, 112, 91-102.	1.9	24
48	Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits. Virology, 2014, 456-457, 310-318.	1.1	5
49	Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology, 2013, 10, 126.	0.9	56
50	Epidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018. Frontiers in Public Health, 0, 10, .	1.3	1